{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T03:14:05Z","timestamp":1792725245606,"version":"4.5.0"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,1,19]],"date-time":"2023-01-19T00:00:00Z","timestamp":1674086400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,1,19]],"date-time":"2023-01-19T00:00:00Z","timestamp":1674086400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81800480 and 81800465"],"award-info":[{"award-number":["81800480 and 81800465"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81800480 and 81800465"],"award-info":[{"award-number":["81800480 and 81800465"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81800480 and 81800465"],"award-info":[{"award-number":["81800480 and 81800465"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81800480 and 81800465"],"award-info":[{"award-number":["81800480 and 81800465"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81800480 and 81800465"],"award-info":[{"award-number":["81800480 and 81800465"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81800480 and 81800465"],"award-info":[{"award-number":["81800480 and 81800465"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Microbiol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Rifaximin has been increasingly applied in irritable bowel syndrome (IBS) treatment. Whether there were differences in the effects of rifaximin on microbiota from different intestinal segments, especially the small intestine where rifaximin predominantly acted, has not been confirmed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      In this study, we used\n                      <jats:italic>Trichinella spiralis<\/jats:italic>\n                      infection to induce post infectious irritable bowel syndrome (PI-IBS) and measured visceral sensitivity of mice by means of abdominal withdrawal reflex (AWR) tests to colorectal distention (CRD). We compared the effects of rifaximin on the composition of ileal, colonic mucosal and fecal microbiota in PI-IBS mice.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Rifaximin significantly reduced AWR scores and increased pain threshold in PI-IBS mice, and this effect was associated with the change in the relative abundance of ileal mucosal microbiota. Rifaximin could obviously decrease ileum mucosal microbiota alpha diversity assessed by Shannon microbial diversity index. Meanwhile, the analysis of beta diversity and relative abundance of microbiota at phylum, family and genus levels showed that rifaximin could improve the microbiota structure of ileal mucosa. However, for colonic mucosal and fecal microbiota, this effect of rifaximin was not obvious. Rifaximin could reshape the correlation of genera between different intestinal segments.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Rifaximin improved visceral hypersensitivity in PI-IBS mice. Rifaximin mainly affected ileal mucosal microbiota, and its improvement effect on IBS might be closely related to the improvement of ileal microbiota structure.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12866-023-02772-6","type":"journal-article","created":{"date-parts":[[2023,1,19]],"date-time":"2023-01-19T04:04:05Z","timestamp":1674101045000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Modulation of the microbiota across different intestinal segments by Rifaximin in PI-IBS mice"],"prefix":"10.1186","volume":"23","author":[{"given":"Shengyan","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gaichao","family":"Hong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gangping","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Qian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Jin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaohua","family":"Hou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,1,19]]},"reference":[{"issue":"6","key":"2772_CR1","doi-asserted-by":"publisher","first-page":"1262","DOI":"10.1053\/j.gastro.2016.02.032","volume":"150","author":"DA Drossman","year":"2016","unstructured":"Drossman DA. Functional gastrointestinal disorders: history, pathophysiology, clinical features, and Rome IV. Gastroenterology. 2016;150(6):1262\u201379.","journal-title":"Gastroenterology"},{"issue":"6","key":"2772_CR2","first-page":"e8860","volume":"12","author":"TGO Achufusi","year":"2020","unstructured":"Achufusi TGO, Sharma A, Zamora EA, Manocha D. Small intestinal bacterial overgrowth: comprehensive review of diagnosis, prevention, and treatment methods. Cureus. 2020;12(6):e8860.","journal-title":"Cureus"},{"issue":"2","key":"2772_CR3","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1007\/s12664-019-00959-2","volume":"38","author":"UC Ghoshal","year":"2019","unstructured":"Ghoshal UC, Rahman MM. Post-infection irritable bowel syndrome in the tropical and subtropical regions: Vibrio cholerae is a new cause of this well-known condition. Indian J Gastroenterol. 2019;38(2):87\u201394.","journal-title":"Indian J Gastroenterol"},{"issue":"1","key":"2772_CR4","doi-asserted-by":"publisher","first-page":"2012","DOI":"10.1038\/s41467-019-09964-7","volume":"10","author":"GB Saffouri","year":"2019","unstructured":"Saffouri GB, Shields-Cutler RR, Chen J, Yang Y, Lekatz HR, Hale VL, Cho JM, Battaglioli EJ, Bhattarai Y, Thompson KJ, et al. Small intestinal microbial dysbiosis underlies symptoms associated with functional gastrointestinal disorders. Nat Commun. 2019;10(1):2012.","journal-title":"Nat Commun"},{"issue":"1","key":"2772_CR5","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1053\/j.gastro.2019.03.049","volume":"157","author":"R Pittayanon","year":"2019","unstructured":"Pittayanon R, Lau JT, Yuan Y, Leontiadis GI, Tse F, Surette M, Moayyedi P. Gut microbiota in patients with irritable bowel syndrome-a systematic review. Gastroenterology. 2019;157(1):97\u2013108.","journal-title":"Gastroenterology"},{"issue":"1","key":"2772_CR6","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1111\/jgh.13471","volume":"32","author":"X Zhuang","year":"2017","unstructured":"Zhuang X, Xiong L, Li L, Li M, Chen M. Alterations of gut microbiota in patients with irritable bowel syndrome: a systematic review and meta-analysis. J Gastroenterol Hepatol. 2017;32(1):28\u201338.","journal-title":"J Gastroenterol Hepatol"},{"key":"2772_CR7","doi-asserted-by":"publisher","first-page":"346","DOI":"10.3389\/fcimb.2019.00346","volume":"9","author":"S Zhu","year":"2019","unstructured":"Zhu S, Liu S, Li H, Zhang Z, Zhang Q, Chen L, Zhao Y, Chen Y, Gu J, Min L, et al. Identification of gut microbiota and metabolites signature in patients with irritable bowel syndrome. Front Cell Infect Microbiol. 2019;9:346.","journal-title":"Front Cell Infect Microbiol"},{"issue":"1","key":"2772_CR8","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1097\/MED.0000000000000523","volume":"27","author":"A Canakis","year":"2020","unstructured":"Canakis A, Haroon M, Weber HC. Irritable bowel syndrome and gut microbiota. Curr Opin Endocrinol Diabetes Obes. 2020;27(1):28\u201335.","journal-title":"Curr Opin Endocrinol Diabetes Obes"},{"issue":"7","key":"2772_CR9","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1080\/17425255.2018.1488964","volume":"14","author":"E Bruzzese","year":"2018","unstructured":"Bruzzese E, Pesce M, Sarnelli G, Guarino A. Pharmacokinetic drug evaluation of rifaximin for treatment of diarrhea-predominant irritable bowel syndrome. Expert Opin Drug Metab Toxicol. 2018;14(7):753\u201360.","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"2772_CR10","doi-asserted-by":"crossref","unstructured":"Steffen R. Rifaximin: a nonabsorbed antimicrobial as a new tool for treatment of travelers\u2019 diarrhea. J Travel Med. 2001;8(Suppl 2):S34-39.","DOI":"10.1111\/j.1708-8305.2001.tb00545.x"},{"issue":"3","key":"2772_CR11","doi-asserted-by":"publisher","first-page":"200","DOI":"10.2174\/1389557515666150722110201","volume":"16","author":"HL DuPont","year":"2015","unstructured":"DuPont HL. Rifaximin: an antibiotic with important biologic effects. Mini Rev Med Chem. 2015;16(3):200\u20135.","journal-title":"Mini Rev Med Chem"},{"issue":"3","key":"2772_CR12","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1517\/13543780902780175","volume":"18","author":"M Pimentel","year":"2009","unstructured":"Pimentel M. Review of rifaximin as treatment for SIBO and IBS. Expert Opin Investig Drugs. 2009;18(3):349\u201358.","journal-title":"Expert Opin Investig Drugs"},{"issue":"8","key":"2772_CR13","doi-asserted-by":"publisher","first-page":"2205","DOI":"10.1128\/AAC.44.8.2205-2206.2000","volume":"44","author":"ZD Jiang","year":"2000","unstructured":"Jiang ZD, Ke S, Palazzini E, Riopel L, Dupont H. In vitro activity and fecal concentration of rifaximin after oral administration. Antimicrob Agents Chemother. 2000;44(8):2205\u20136.","journal-title":"Antimicrob Agents Chemother"},{"issue":"1","key":"2772_CR14","first-page":"19","volume":"5","author":"DE Baker","year":"2005","unstructured":"Baker DE. Rifaximin: a nonabsorbed oral antibiotic. Rev Gastroenterol Disord. 2005;5(1):19\u201330.","journal-title":"Rev Gastroenterol Disord"},{"issue":"1","key":"2772_CR15","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1056\/NEJMoa1004409","volume":"364","author":"M Pimentel","year":"2011","unstructured":"Pimentel M, Lembo A, Chey WD, Zakko S, Ringel Y, Yu J, Mareya SM, Shaw AL, Bortey E, Forbes WP. Rifaximin therapy for patients with irritable bowel syndrome without constipation. N Engl J Med. 2011;364(1):22\u201332.","journal-title":"N Engl J Med"},{"issue":"2","key":"2772_CR16","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1053\/j.gastro.2013.10.026","volume":"146","author":"D Xu","year":"2014","unstructured":"Xu D, Gao J, Gillilland M 3rd, Wu X, Song I, Kao JY, Owyang C. Rifaximin alters intestinal bacteria and prevents stress-induced gut inflammation and visceral hyperalgesia in rats. Gastroenterology. 2014;146(2):484-496.e484.","journal-title":"Gastroenterology"},{"issue":"1","key":"2772_CR17","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1097\/MED.0000000000000302","volume":"24","author":"HC Weber","year":"2017","unstructured":"Weber HC. New treatment options for irritable bowel syndrome with predominant diarrhea. Curr Opin Endocrinol Diabetes Obes. 2017;24(1):25\u201330.","journal-title":"Curr Opin Endocrinol Diabetes Obes"},{"issue":"Suppl 1","key":"2772_CR18","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1111\/apt.13437","volume":"43","author":"M Pimentel","year":"2016","unstructured":"Pimentel M. Review article: potential mechanisms of action of rifaximin in the management of irritable bowel syndrome with diarrhoea. Aliment Pharmacol Ther. 2016;43(Suppl 1):37\u201349.","journal-title":"Aliment Pharmacol Ther"},{"issue":"10","key":"2772_CR19","doi-asserted-by":"publisher","first-page":"1211","DOI":"10.1111\/apt.13399","volume":"42","author":"I Rangel","year":"2015","unstructured":"Rangel I, Sundin J, Fuentes S, Repsilber D, de Vos WM, Brummer RJ. The relationship between faecal-associated and mucosal-associated microbiota in irritable bowel syndrome patients and healthy subjects. Aliment Pharmacol Ther. 2015;42(10):1211\u201321.","journal-title":"Aliment Pharmacol Ther"},{"key":"2772_CR20","doi-asserted-by":"publisher","first-page":"517052","DOI":"10.1155\/2009\/517052","volume":"2009","author":"Y Fu","year":"2009","unstructured":"Fu Y, Wang W, Tong J, Pan Q, Long Y, Qian W, Hou X. Th17: a new participant in gut dysfunction in mice infected with Trichinella spiralis. Mediators Inflamm. 2009;2009:517052.","journal-title":"Mediators Inflamm"},{"issue":"2\u20133","key":"2772_CR21","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1016\/j.ejphar.2008.02.095","volume":"585","author":"AD Kraneveld","year":"2008","unstructured":"Kraneveld AD, Rijnierse A, Nijkamp FP, Garssen J. Neuro-immune interactions in inflammatory bowel disease and irritable bowel syndrome: future therapeutic targets. Eur J Pharmacol. 2008;585(2\u20133):361\u201374.","journal-title":"Eur J Pharmacol"},{"issue":"4","key":"2772_CR22","doi-asserted-by":"publisher","first-page":"1224","DOI":"10.1053\/gast.1997.v113.pm9322517","volume":"113","author":"G Barbara","year":"1997","unstructured":"Barbara G, Vallance BA, Collins SM. Persistent intestinal neuromuscular dysfunction after acute nematode infection in mice. Gastroenterology. 1997;113(4):1224\u201332.","journal-title":"Gastroenterology"},{"issue":"1","key":"2772_CR23","doi-asserted-by":"publisher","first-page":"51","DOI":"10.2307\/3277345","volume":"55","author":"GA Castro","year":"1969","unstructured":"Castro GA, Fairbairn D. Carbohydrates and lipids in Trichinella spiralis larvae and their utilization in vitro. J Parasitol. 1969;55(1):51\u20138.","journal-title":"J Parasitol"},{"issue":"7","key":"2772_CR24","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1111\/1751-2980.12374","volume":"17","author":"QQ Qi","year":"2016","unstructured":"Qi QQ, Chen FX, Zhao DY, Li LX, Wang P, Li YQ, Zuo XL. Colonic mucosal N-methyl-D-aspartate receptor mediated visceral hypersensitivity in a mouse model of irritable bowel syndrome. J Dig Dis. 2016;17(7):448\u201357.","journal-title":"J Dig Dis"},{"issue":"36","key":"2772_CR25","doi-asserted-by":"publisher","first-page":"5469","DOI":"10.3748\/wjg.v25.i36.5469","volume":"25","author":"Q Zhao","year":"2019","unstructured":"Zhao Q, Yang WR, Wang XH, Li GQ, Xu LQ, Cui X, Liu Y, Zuo XL. Clostridium butyricum alleviates intestinal low-grade inflammation in TNBS-induced irritable bowel syndrome in mice by regulating functional status of lamina propria dendritic cells. World J Gastroenterol. 2019;25(36):5469\u201382.","journal-title":"World J Gastroenterol"},{"key":"2772_CR26","unstructured":"Deiteren A, de Wit A, van der Linden L, De Man JG, Pelckmans PA, De Winter BY. Irritable bowel syndrome and visceral hypersensitivity\u202f: risk factors and pathophysiological mechanisms. Acta Gastroenterol Belg. 2016;79(1):29\u201338."},{"issue":"7","key":"2772_CR27","doi-asserted-by":"publisher","first-page":"1890","DOI":"10.1007\/s10620-018-5086-4","volume":"63","author":"N Maharshak","year":"2018","unstructured":"Maharshak N, Ringel Y, Katibian D, Lundqvist A, Sartor RB, Carroll IM, Ringel-Kulka T. Fecal and mucosa-associated intestinal microbiota in patients with diarrhea-predominant irritable bowel syndrome. Dig Dis Sci. 2018;63(7):1890\u20139.","journal-title":"Dig Dis Sci"},{"issue":"4","key":"2772_CR28","doi-asserted-by":"publisher","first-page":"410","DOI":"10.3109\/00365521.2015.1116107","volume":"51","author":"CS Chung","year":"2016","unstructured":"Chung CS, Chang PF, Liao CH, Lee TH, Chen Y, Lee YC, Wu MS, Wang HP, Ni YH. Differences of microbiota in small bowel and faeces between irritable bowel syndrome patients and healthy subjects. Scand J Gastroenterol. 2016;51(4):410\u20139.","journal-title":"Scand J Gastroenterol"},{"issue":"1","key":"2772_CR29","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1080\/19490976.2018.1460013","volume":"10","author":"AA Fodor","year":"2019","unstructured":"Fodor AA, Pimentel M, Chey WD, Lembo A, Golden PL, Israel RJ, Carroll IM. Rifaximin is associated with modest, transient decreases in multiple taxa in the gut microbiota of patients with diarrhoea-predominant irritable bowel syndrome. Gut Microbes. 2019;10(1):22\u201333.","journal-title":"Gut Microbes"},{"issue":"10","key":"2772_CR30","doi-asserted-by":"publisher","first-page":"2449","DOI":"10.3748\/wjg.v20.i10.2449","volume":"20","author":"W Bye","year":"2014","unstructured":"Bye W, Ishaq N, Bolin TD, Duncombe VM, Riordan SM. Overgrowth of the indigenous gut microbiome and irritable bowel syndrome. World J Gastroenterol. 2014;20(10):2449\u201355.","journal-title":"World J Gastroenterol"},{"issue":"5","key":"2772_CR31","doi-asserted-by":"publisher","first-page":"1474","DOI":"10.3390\/nu12051474","volume":"12","author":"F Magne","year":"2020","unstructured":"Magne F, Gotteland M, Gauthier L, Zazueta A, Pesoa S, Navarrete P, Balamurugan R. The Firmicutes\/Bacteroidetes Ratio: A Relevant Marker of Gut Dysbiosis in Obese Patients? Nutrients. 2020;12(5):1474.","journal-title":"Nutrients"},{"issue":"10","key":"2772_CR32","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.1111\/apt.12728","volume":"39","author":"HL Dupont","year":"2014","unstructured":"Dupont HL. Review article: evidence for the role of gut microbiota in irritable bowel syndrome and its potential influence on therapeutic targets. Aliment Pharmacol Ther. 2014;39(10):1033\u201342.","journal-title":"Aliment Pharmacol Ther"},{"issue":"8","key":"2772_CR33","doi-asserted-by":"publisher","first-page":"698","DOI":"10.1097\/PSY.0000000000000630","volume":"80","author":"J Peter","year":"2018","unstructured":"Peter J, Fournier C, Durdevic M, Knoblich L, Keip B, Dejaco C, Trauner M, Moser G. A microbial signature of psychological distress in irritable bowel syndrome. Psychosom Med. 2018;80(8):698\u2013709.","journal-title":"Psychosom Med"},{"issue":"11","key":"2772_CR34","doi-asserted-by":"publisher","first-page":"3619","DOI":"10.3390\/ijms19113619","volume":"19","author":"J Peter","year":"2018","unstructured":"Peter J, Fournier C, Keip B, Rittershaus N, Stephanou-Rieser N, Durdevic M, Dejaco C, Michalski M, Moser G. Intestinal microbiome in irritable bowel syndrome before and after gut-directed hypnotherapy. Int J Mol Sci. 2018;19(11):3619.","journal-title":"Int J Mol Sci"},{"issue":"2","key":"2772_CR35","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1111\/apt.15325","volume":"50","author":"M Zamani","year":"2019","unstructured":"Zamani M, Alizadeh-Tabari S, Zamani V. Systematic review with meta-analysis: the prevalence of anxiety and depression in patients with irritable bowel syndrome. Aliment Pharmacol Ther. 2019;50(2):132\u201343.","journal-title":"Aliment Pharmacol Ther"},{"issue":"6","key":"2772_CR36","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1111\/nmo.12793","volume":"28","author":"IS Lee","year":"2016","unstructured":"Lee IS, Wang H, Chae Y, Preissl H, Enck P. Functional neuroimaging studies in functional dyspepsia patients: a systematic review. Neurogastroenterol Motil. 2016;28(6):793\u2013805.","journal-title":"Neurogastroenterol Motil"},{"issue":"9","key":"2772_CR37","doi-asserted-by":"publisher","first-page":"3618","DOI":"10.1128\/AAC.00161-10","volume":"54","author":"C Darkoh","year":"2010","unstructured":"Darkoh C, Lichtenberger LM, Ajami N, Dial EJ, Jiang ZD, DuPont HL. Bile acids improve the antimicrobial effect of rifaximin. Antimicrob Agents Chemother. 2010;54(9):3618\u201324.","journal-title":"Antimicrob Agents Chemother"},{"issue":"3","key":"2772_CR38","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1016\/j.ijantimicag.2013.12.008","volume":"43","author":"A Pistiki","year":"2014","unstructured":"Pistiki A, Galani I, Pyleris E, Barbatzas C, Pimentel M, Giamarellos-Bourboulis EJ. In vitro activity of rifaximin against isolates from patients with small intestinal bacterial overgrowth. Int J Antimicrob Agents. 2014;43(3):236\u201341.","journal-title":"Int J Antimicrob Agents"},{"issue":"7","key":"2772_CR39","doi-asserted-by":"publisher","first-page":"2219","DOI":"10.3748\/wjg.v22.i7.2219","volume":"22","author":"E Distrutti","year":"2016","unstructured":"Distrutti E, Monaldi L, Ricci P, Fiorucci S. Gut microbiota role in irritable bowel syndrome: New therapeutic strategies. World J Gastroenterol. 2016;22(7):2219\u201341.","journal-title":"World J Gastroenterol"},{"issue":"6","key":"2772_CR40","doi-asserted-by":"publisher","first-page":"e13182","DOI":"10.14814\/phy2.13182","volume":"5","author":"K Touw","year":"2017","unstructured":"Touw K, Ringus DL, Hubert N, Wang Y, Leone VA, Nadimpalli A, Theriault BR, Huang YE, Tune JD, Herring PB, et al. Mutual reinforcement of pathophysiological host-microbe interactions in intestinal stasis models. Physiol Rep. 2017;5(6):e13182.","journal-title":"Physiol Rep"},{"issue":"1","key":"2772_CR41","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1111\/jgh.15104","volume":"36","author":"L Brunkwall","year":"2021","unstructured":"Brunkwall L, Ericson U, Nilsson PM, Orho-Melander M, Ohlsson B. Self-reported bowel symptoms are associated with differences in overall gut microbiota composition and enrichment of Blautia in a population-based cohort. J Gastroenterol Hepatol. 2021;36(1):174\u201380.","journal-title":"J Gastroenterol Hepatol"}],"container-title":["BMC Microbiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12866-023-02772-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12866-023-02772-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12866-023-02772-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,4]],"date-time":"2023-12-04T19:59:11Z","timestamp":1701719951000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcmicrobiol.biomedcentral.com\/articles\/10.1186\/s12866-023-02772-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1,19]]},"references-count":41,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["2772"],"URL":"https:\/\/doi.org\/10.1186\/s12866-023-02772-6","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-1794729\/v1","asserted-by":"object"}]},"ISSN":["1471-2180"],"issn-type":[{"value":"1471-2180","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,1,19]]},"assertion":[{"value":"25 June 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 January 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 January 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Male NIH Swiss mice were obtained from Medical Animal Laboratory center of Guangdong (No. SCXK2008-0002). All animal work was reviewed and approved based on the Ethics Committee of Animal Experimentation, Tongji Medical College. (Ethical approval reference number:2019S 3581). All methods were carried out in accordance with relevant guidelines and regulations. This study was carried out in compliance with the ARRIVE guidelines.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable in this article, for there are no information or images that could lead to identification of a study participant.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declared no potential conflicts of interest with respect to the research, author- ship, and\/or publication of this article.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"22"}}